SMA Newsroom

Call for Research Lay Summary of the Projects

Call for Research website

Our Call for Research Projects

<h2><strong>We are proud to announce the five scientific projects that have been selected for funding through our Call for Research no. 12.</strong></h2>
<p><strong> </strong></p>
<h2>&nbsp;</h2>

Call for Research no. 12. Learn about the shortlisted projects!

Please find the letter here

<p><span style="font-family: Trebuchet MS, sans-serif;"><span style="font-size: 14.6667px;">We are pleased to share the latest Community Letter issued by Roche, providing an update on their ongoing efforts in Spinal Muscular Atrophy (SMA) in 2024. The letter includes the latest developments on risdiplam and Roche&rsquo;s SMA clinical development program.</span></span></p>

Community Update Roche: End of Year Community Letter

For further details

<p>Biohaven released the results from their RESILIENT SMA clinical trial, and they did not meet the primary endpoint. Biohaven is currently analysing the data further and is engaging in discussion with Health Authorities.&nbsp;</p>

Community Update Biohaven: RESILIENT Letter to SMA Community

Read full article here.

<p>We're excited to announce that SMA News Today has featured our OdySMA real-life stories initiative, as part of their latest publication!</p>

SMA Newsroom

Call for Research no. 12. Learn about the shortlisted projects!

We are proud to announce the five scientific projects that have been selected for funding through our Call for Research no. 12.

Community Update Roche: End of Year Community Letter

Community Update Biohaven: RESILIENT Letter to SMA Community

SMA News Today latest article: "SMA Europe inviting patients to talk of how treatment has changed life."

Categories